Tourmaline Bio, Inc. - Common stock, par value $0.0001 per share (TRML) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2023 to Q4 2025

Type / Class
Equity / Common stock, par value $0.0001 per share
Symbol
TRML
Shares outstanding
25,669,673
Price per share
$47.98
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
21,618,938
Total reported value
$1,034,037,845
% of total 13F portfolios
0%
Share change
-2,449,700
Value change
+$121,144,493
Number of holders
134
Price from insider filings
$47.98
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Tourmaline Bio, Inc. - Common stock, par value $0.0001 per share (TRML) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Avoro Capital Advisors LLC 10% $58,931,098 2,555,555 Avoro Capital Advisors LLC 30 Jun 2025
QVT Financial LP 8.4% +44% $49,686,298 +$15,710,409 2,154,653 +46% QVT Financial LP 30 Jun 2025
BlackRock, Inc. 5.5% $67,527,642 1,411,832 BlackRock, Inc. 30 Sep 2025
Blue Owl Capital Holdings LP 4.2% $13,621,031 1,079,321 Blue Owl Capital Holdings LP 31 Dec 2024

As of 30 Sep 2025, 134 institutional investors reported holding 21,618,938 shares of Tourmaline Bio, Inc. - Common stock, par value $0.0001 per share (TRML). This represents 84% of the company’s total 25,669,673 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Tourmaline Bio, Inc. - Common stock, par value $0.0001 per share (TRML) together control 73% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Avoro Capital Advisors LLC 10% 2,555,555 0% 1.6% $122,232,196
QVT Financial LP 8.4% 2,154,653 0% 11% $103,057,053
BlackRock, Inc. 5.9% 1,517,777 -7.1% 0% $72,595,275
TCG Crossover Management, LLC 5.1% 1,311,783 -11% 3.1% $62,742,581
Pfizer Inc 5% 1,272,214 0% 14% $60,849,996
VANGUARD GROUP INC 4.5% 1,165,607 -3.4% 0% $55,750,983
FIL Ltd 4% 1,027,690 0.04% $49,154,413
Magnetar Financial LLC 3.8% 966,129 0.28% $46,209,950
QIMING U.S. VENTURES MANAGEMENT, LLC 2.9% 741,691 0% 64% $35,475,081
First Trust Capital Management L.P. 2.7% 695,757 2.1% $33,278,057
TIG Advisors, LLC 2.4% 619,763 1.8% $29,643,264
Vivo Capital, LLC 2.3% 591,882 0% 2.3% $28,309,716
ALLIANCEBERNSTEIN L.P. 2.1% 539,961 +1986% 0.01% $25,826,335
NEXPOINT ASSET MANAGEMENT, L.P. 1.8% 455,360 1.9% $21,779,869
GEODE CAPITAL MANAGEMENT, LLC 1.8% 453,952 -2.8% 0% $21,716,300
STATE STREET CORP 1.6% 415,970 -9.5% 0% $19,895,845
GOLDMAN SACHS GROUP INC 1.5% 376,738 +110% 0% $18,019,379
AQR Arbitrage LLC 1.5% 374,785 0.46% $17,925,967
ACUTA CAPITAL PARTNERS, LLC 1% 268,451 -5.4% 13% $12,840,011
MORGAN STANLEY 0.98% 252,093 -31% 0% $12,057,609
NAN FUNG TRINITY (HK) LTD 0.88% 227,090 0% 1.1% $10,861,715
Versor Investments LP 0.85% 217,221 1.9% $10,389,680
ALPINE ASSOCIATES MANAGEMENT INC. 0.76% 196,177 0.57% $9,383,146
MILLENNIUM MANAGEMENT LLC 0.74% 190,625 -22% 0.01% $9,117,594
GLAZER CAPITAL, LLC 0.7% 180,155 0.29% $8,617,000

Institutional Holders of Tourmaline Bio, Inc. - Common stock, par value $0.0001 per share (TRML) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$1,096,006 $47.98 0
2025 Q3 21,618,938 $1,034,037,845 +$121,144,493 $47.83 134
2025 Q2 24,065,900 $384,816,806 +$2,889,811 $15.99 107
2025 Q1 23,949,691 $364,277,293 +$11,366,241 $15.21 107
2024 Q4 22,862,128 $463,647,500 +$8,433,550 $20.28 100
2024 Q3 21,032,430 $540,746,931 +$2,040,168 $25.71 90
2024 Q2 21,157,029 $272,081,168 -$49,171,054 $12.86 83
2024 Q1 20,558,012 $469,902,038 +$169,163,428 $22.90 97
2023 Q4 14,500 $379,610 +$379,610 $26.18 1